Published by
em
Par
The Federal University of Minas Gerais (UFMG) has opened registration for those who wish to participate in stages 1 and 2 of clinical trials of its COVID-19 vaccine. The vaccine is expected to be available for inoculation in the population from 2025.
The vaccine is developed at the Vaccine Technology Center (CT-Vaccines), a biotechnology medium of the Belo Horizonte Technology Park – BH-Tec – and is the result of a partnership between UFMG and the René Rachou Institute, a regional unit of the Oswaldo Cruz Foundation (Fiocruz), a clinical establishment attached to the Ministry of Health.
Phase 1 volunteers must be between the ages of 18 and 85, healthy, not having had COVID-19, having won the initial two doses of the CoronaVac vaccine and one booster dose from Pfizer at least nine months ago. Breastfeeding. For phase 2, the fact of having already contracted the disease will not be an impediment, maintaining the rest of the contracting criteria.
Initially, the studies involve small teams of healthy adults. 72 volunteers will be chosen for Phase 1 and 360 for Phase 2. If the effects are satisfactory, Phase 3 will be conducted with 4,000 to 5,000 participants to compare its effectiveness.
In preclinical animal tests, the effects have been promising. A fairly good reaction was observed in mice. Inoculation induced one hundred percent protection. Safety and immunogenicity tests have also been conducted in non-human primates. These experiments aim to stumble upon imaginable-looking effects and verify the generation of antibodies.
The concern for the environment is in the admission behavior of Brazilians
Transition team proposes exclusion of BRL bi from spending cap
Portalrondonia. com de Notícias de Rondônia e Região envie sua notícia para [email protected] ou pelo nosso whats (6nine) nine ninenine426406